| Literature DB >> 29922270 |
Emma Reece1, Sean Doyle2, Peter Greally3, Julie Renwick1, Siobhán McClean4.
Abstract
Many cystic fibrosis (CF) airway infections are considered to be polymicrobial and microbe-microbe interactions may play an important role in disease pathology. Pseudomonas aeruginosa and Aspergillus fumigatus are the most prevalent bacterial and fungal pathogens isolated from the CF airway, respectively. We have previously shown that patients co-colonized with these pathogens had comparable outcomes to those chronically colonized with P. aeruginosa. Our objective was to examine the interactions between A. fumigatus and P. aeruginosa, specifically the effects of co-colonization on biofilm formation, virulence and host pro-inflammatory responses. Our findings suggest that co-infections of A. fumigatus and P. aeruginosa in the Galleria mellonella acute infection model showed that pre-exposure of larvae to sub-lethal inocula of A. fumigatus increased the mortality caused by subsequent P. aeruginosa infection. Co-infection of human bronchial epithelial cells (CFBE41o-) with both pathogens did not enhance IL-6 and IL-8 production beyond the levels observed following single infections. In addition, both pathogens stimulated cytokine secretion via the same two mitogen-activated protein kinases (MAPKs) signaling pathways, ERK and p38. Mixed species biofilms showed overall reduced biofilm development with crystal violet staining. Quantification by species-specific qPCR revealed that both pathogens had mutually antagonistic effects on each other. A. fumigatus supernatants showed strong anti-Pseudomonal activity and gliotoxin was the main active agent. Gliotoxin resulted in varying levels of anti-biofilm activity toward other bacteria commonly found in the CF airways. Gliotoxin produced by A. fumigatus colonizing the CF airways may have a significant impact on the CF airway microbiome composition with potential clinical implications.Entities:
Keywords: Aspergillus fumigatus; Pseudomonas aeruginosa; biofilm; co-colonization; cystic fibrosis; gliotoxin; inflammation
Year: 2018 PMID: 29922270 PMCID: PMC5996130 DOI: 10.3389/fmicb.2018.01205
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Strains used in this study.
| Strain name | Source | Strain type | Reference |
|---|---|---|---|
| PAref1 | ATCC | Reference | ATCC 27853 |
| PA27 | CF patient | Mucoid | IST 27 |
| PA27N | CF patient | Non-mucoid | IST 27N |
| PAco1 | CF patient | Co-colonizer | This study |
| PAco2 | CF patient | Co-colonizer | This study |
| AFref1 | ATCC | Reference | ATCC Af293 |
| AFref2 | ATCC | Reference | ATCC 26933 |
| AF1 | CF patient | Clinical | This study |
| AF2 | CF patient | Clinical | This study |
| AFco1 | CF patient | Co-colonizer | This study |
| AFco2 | CF patient | Co-colonizer | This study |
| ΔgliG | ATCC | Mutant | |
| ΔgliGc | ATCC | Complement | |
| ATCC | Reference | ATCC 17666 | |
| ATCC | Reference | ATCC 25923 | |
| NCTC | Reference | 8468 | |
| Patient | Clinical | This study | |
| BCCM/LMG | Clinical | LMG 13010 | |
Reduction in mixed species biofilm formation in comparison to single species biofilms as measured by the crystal violet assay.
| Inhibition in biofilm formation (%) ± standard deviation∗ | |||||
|---|---|---|---|---|---|
| PA27 | PA27N | PAco1 | PAco2 | PAref | |
| AFref1 | 71.8 ± 2.6 | 68.4 ± 3.4 | 66.3 ± 0.6 | 64.2 ± 4.2 | 60.5 ±6 |
| AF1 | 77.4 ± 4 | 74.2 ± 3.3 | 73.5 ± 1.5 | 72.8 ± 1.3 | 66.4 ± 3.6 |
| AF2 | 79.1 ± 3.3 | 69.4 ± 1.3 | 74.6 ± 1.1 | 68.2 ± 4.4 | 62.5 ± 6 |
| AFco1 | 74.2 ± 7.7 | 68 ± 4.1 | 62.3 ± 5.3 | 70.2 ± 2.7 | 67.1 ± 5.2 |
| AFco2 | 77.8 ± 1.3 | 68.6 ± 2.4 | 66.2 ± 4.4 | 63.3 ± 2.2 | 62.9 ± 4.4 |
Reduction of P. aeruginosa biofilm formation when treated with 72 h CSNs from A. fumigatus.
| Inhibition in biofilm formation (%) ± standard deviation∗ | |||||
|---|---|---|---|---|---|
| AFref1 | AF1 | AF2 | AFco1 | AFco2 | |
| PA27 | 77.2# ± 12.5 | 77.6 ± 9.8 | 72.8# ± 6.1 | 84.1# ± 22.7 | 74.2 ± 13.8 |
| PA27N | 80.0 ± 4.8 | 83.6 ± 8.4 | 76.8 ± 2.5 | 79.3 ± 4.2 | 74.9 ± 4.8 |
| PAco1 | 81.0# ± 1.4 | 73.6 ± 9.6 | 78.7 ± 4.6 | 75.2 ± 3 | 80.0 ± 12.8 |
| PAco2 | 85.4# ± 14.1 | 83.2# ± 12.2 | 86.4# ± 12 | 85.8# ± 26 | 88.3# ± 22.9 |
| PAref1 | 81.8 ± 3.2 | 77.6 ± 2.5 | 75.8 ± 2.4 | 77.1 ± 1.7 | 76.5 ± 10.4 |